Cell and Gene Therapy Tech Talks
Cell and gene therapies continue to expand rapidly, with an anticipated exponential growth. This rapid growth has left an urgent need for industry scientists to gather and share lessons learned concerning bioanalytical, biomarker and regulatory strategies. This series provides insight from our experts into a variety of cell and gene therapy (CGT) modalities in the bioanalytical community, with detailed discussions that leverage their experience with technologies within this CGT space.
Video 1: Molecular Genomics: Selecting qPCR and ddPCR
Tim Lochmann, Ph.D., senior research scientist in the molecular lab department, discusses when to use quantitative PCR (qPCR) versus droplet digital PCR (ddPCR).
Video 2: AAV Assay Development and AAV Cell-Based Neutralizing Assay Development
Molly Crowe, Ph.D., and Rebecca Garshick, Ph.D., talk about some best practices for the development and validation of adeno-associated virus (AAV) assays and cell based NAb assays for AAVs.
Video 3: Pre-Existing Antibodies: Considerations for Cell and Gene Therapy Products
Kelli Phillips discusses pre-existing antibodies, why they are concerning, and strategies to mitigate their impact.
Video 4: Bioanalysis of Oligonucleotides: Ligand Binding and Chromatography
KFumin Li, Ph.D., and Eric Tewalt, Ph.D., compare the analysis of oligonucleotides via ligand binding and chromatography.
Video 5: Enzymatic Assays
Janine Micheli, Ph.D., talks about challenges with enzyme activity assay development and suggests several potential mitigation strategies.
Video 6: Flow Cytometry in Cell and Gene Therapy
Vellalore N. Kakkanaiah, Ph.D., discusses applications of flow cytometry in cell and gene therapy, such as in clinical diagnosis, drug discovery and development, and microbiology.